Anti-CALHM1 Antibody

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of senile plaques comprised of aggregated amyloid-beta (Abeta) peptides produced by the endoproteolysis of the amyloid precursor protein (APP) . The calcium homeostasis modulator 1 (CALHM1) is a recently identified multipass transmembrane glycoprotein that controls cytosolic Ca2+ concentration and Abeta levels. While some studies suggest CALHM1 is significantly associated with risk of AD, other reports suggest there is no link. CALHM1 has been suggested to modulate the Ca2+-dependent proteolytic process of APP through controlling the level of cytosolic Ca2+.

CALHM1 antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human CALHM1. The immunogen is located within amino acids 60 - 110 of CALHM1.

Predominantly expressed in adult brain. Detected also in retinoic acid-differentiated SH-SY5Y cells. Specifically expressed in circumvallate taste bud cells.

Pore-forming subunit of a voltage-gated ion channel required for sensory perception of sweet, bitter and umami tastes. Specifically present in type II taste bud cells, where it plays a central role in sweet, bitter and umami taste perception by inducing ATP release from the cell, ATP acting as a neurotransmitter to activate afferent neural gustatory pathways. Acts both as a voltage-gated and calcium-activated ion channel: mediates neuronal excitability in response to changes in extracellular Ca (2+) concentration. Has poor ion selectivity and forms a wide pore (around 14 Angstroms) that mediates permeation of Ca (2+), Na (+) and K (+), as well as permeation of monovalent anions. Acts as an activator of the ERK1 and ERK2 cascade. Triggers endoplasmic reticulum stress by reducing the calcium content of the endoplasmic reticulum. May indirectly control amyloid precursor protein (APP) proteolysis and aggregated amyloid-beta (Abeta) peptides levels in a Ca (2+) dependent manner.

CALHM1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.